Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Shares Climb 6.6 Percent on Strong Q4 Revenue Growth

NEW YORK, Feb. 22 (GenomeWeb News) - CombiMatrix today reported fourth quarter revenues of $3.6 million versus $522,000 in the year-ago period.


Shares in CombiMatrix were up 6.55 percent, or $.11, at $1.79 in mid-afternoon trading on the news.


Total receipts for the period included $2.3 million in previously deferred revenues recognized from CombiMatrix's completion of its R&D agreement with Toppan Printing.


R&D costs increased 25 percent to $1.7 million from $1.4 million in the year-ago period.


Net losses in the fourth quarter narrowed 57 percent to $1.8 million from $4.1 million, CombiMatrix said.


The unit had around $20.2 million in cash and short-term investments as of Dec.31.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.